Publication details
Plasma cell phenotype in multiple myeloma - retrospective data analysis
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Plasma cell (PC) phenotype in multiple myeloma (MM) is very heterogeneous and could correlate with presence of genetic abnormalities and/or morphological subtypes Thus expression of some markers could be related to patient’s prognosis as well. The aim of work was to analyse antigenic profile together with cytogenetic aberrations and morphology and especially to find relationship between phenotype and prognosis of MM patients, if any. Analyses were done in 134 newly diagnosed untreated MM patients. Plasma cells were detected in all patients with median 15.5% (range 0.1-80.4). Clonal CD19+ PCs were found in 2 patient with del(13)(q14). Presence of residual normal CD19+ PCs correlated with significantly better clinical outcome as lower beta2m, serum MIG and lower PC infiltration. Positivity for CD56 correlated with lower expression of CD20, CD27 and CD28 (p<0.01), also with less mature morphology (p<0.05), and cohort of patients with CD56+ PCs has lower beta2m than cohort with CD56- PCs (p<0.001). CD20+ PCs significantly correlated with higher expression of CD28, CD117 and lower expression of CD56 on PCs, and surprisingly, CD20+ samples were more mature PCs than CD20- samples. Marker CD27 was less expressed in group with higher CD56+ PCs number (p<0.001) and CD27+ PCs were more mature plasmocytes. CD28- PCs were more often type II and type I proplasmocytes than CD28+ PCs. Expression of CD117 on PCs correlated with hyperdiploidy [41.0% vs 0.0%; p<0.05], on the other hand, negativity for CD117 was associated with del(13)(q14) [34.0% vs 1.2%; p<0.01]. Our results shown plasma cells heterogeneity in phenotypic, cytogenetic and morphology profiles and CD117 (its positivity and/or negativity) is the only marker corresponding to chromosomal abnormalities. Phenotypic data related to the treatment response, time to progression, overall survival of patients etc., will be presented as well. |
| Related projects: |